Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 23, 2015 9:14 AM ET


Company Overview of EnGeneIC Ltd.

Company Overview

EnGeneIC Ltd., a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company’s drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo. It serves customers in Australia, Singapore, Japan, and India. The company was incorporated in 2000 and is based in Lane Cove West, Australia.

2/25 Sirius Road

Lane Cove West, NSW 2066


Founded in 2000


61 2 9420 5844


61 2 9878 5922

Key Executives for EnGeneIC Ltd.

Co-Managing Director and Director
Founder, Co-Managing Director and Director
Compensation as of Fiscal Year 2014.

EnGeneIC Ltd. Key Developments

EnGeneIC Ltd. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM

EnGeneIC Ltd. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Himanshu Brahmbhatt, Co-Managing Director and Director, Jennifer A. MacDiarmid, Founder, Co-Managing Director and Director.

EnGeneIC Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:30 AM

EnGeneIC Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

EnGeneIC Ltd. Unveils Clinical Development Strategy for EDV Nanocell Technology

EnGeneIC Ltd. announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor. In June 2014, EnGeneIC completed a Phase 1 trial in recurrent glioma in Australia and now plans to submit an IND and commence the U.S. clinical program in early 2015. EnGeneIC's bacterially-derived EDV nanocells are a powerful nanoparticle drug delivery system designed to directly target and effectively kill tumor cells with minimal toxicity, while at the same time stimulate the immune system's natural anti-tumor response. Intravenously injected EDV nanocells exit the leaky vascular system only within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver a drug payload of up to one million drug molecules per nanocell. In parallel, the bacterial cell wall of the nanocells stimulates key components of the immune system, which are then activated to seek out and destroy cancer cells.

Recent Private Companies Transactions

Private Placement
December 12, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EnGeneIC Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at